Pharmacyclics Switzerland GmbH clinical trials

Acquired by AbbVie, May 26, 2015 · source ↗

The registry lists 2 studies whose lead sponsor is Pharmacyclics Switzerland GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 30, 2025.

Before and after it joined AbbVie

First submitted before Pharmacyclics Switzerland GmbH became part of AbbVie: 0
First submitted after Pharmacyclics Switzerland GmbH became part of AbbVie: 2
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 1
Active, not recruiting: 1

Phase

Phase 4: 1
Phase 2: 1

Where

Spain: 2
Czechia: 2
Italy: 2
Turkey: 2
France: 1
United Kingdom: 1

Registry sponsor names on this page

Pharmacyclics Switzerland GmbH2 studies

Something wrong with this grouping? Tell us on the AbbVie page.

Studies

Recruiting first, then most recently updated. Showing 2 of 2. All AbbVie studies →

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Active, not recruitingNCT03229200Phase 4
Sponsor listed in the registry: Pharmacyclics Switzerland GmbH · First submitted after Pharmacyclics Switzerland GmbH became part of AbbVie
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaCompletedNCT02902965Phase 2
Sponsor listed in the registry: Pharmacyclics Switzerland GmbH · First submitted after Pharmacyclics Switzerland GmbH became part of AbbVie